AngioDynamics Introduces DuraMax™ Chronic Dialysis Catheter at 2009 CIRSE Scientific Meeting

September 23, 2009 at 12:00 AM EDT
AngioDynamics Introduces DuraMax™ Chronic Dialysis Catheter at 2009 CIRSE Scientific Meeting

QUEENSBURY, N.Y. September 23, 2009 — AngioDynamics (NASDAQ: ANGO) has introduced the DuraMax™ stepped chronic dialysis catheter at the 2009 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Scientific Meeting, held in Lisbon, Portugal, September 19-23. The new catheter employs Curved Tip™ Catheter Technology that is designed to provide higher blood flow and lower recirculation, even if the catheter becomes positioned against a blood vessel wall. This design approach eliminates the need for side holes common in other catheters, reducing the potential for clots.

“DuraMax’s curved tip simplifies catheter placement for our staff, allowing better blood flow, reducing the potential for clotting and eliminating guesswork about the position of the catheter,” said Dr. Marc Glickman of Vascular & Transplant Specialists, Virginia Beach, VA. “Our practice is committed to providing our patients with the best quality of care, and we are pleased to offer the next generation benefits that DuraMax represents.”

DuraMax employs AngioDynamics’ proprietary Curved Tip Catheter Technology platform, a design approach intended to allow the catheter to be position non-dependent. It features a unique proprietary guidewire lumen offering a low profile, tapered tip design for ease of insertion into blood vessels. A double-valved introducer reduces the chance of air embolism. The new catheter is made from Durathane® polymer material, engineered for long-term durability, and resistance to alcohol and other common agents used to care for the entry site. In addition, DuraMax luer fittings are made from thermoplastic polyurethane, a robust compound that further increases the catheter’s long-term durability.

“The DuraMax catheter highlights the continuing commitment to innovation that makes AngioDynamics’ products attractive choices to physicians seeking the best available treatment options,” said Jan Keltjens, AngioDynamics CEO. “Curved Tip Catheter Technology provides a significant improvement for patient care compared to the currently available technology.”

The DuraMax catheter and accompanying procedure kit are cleared by the U.S. Food and Drug Administration (FDA) for attaining long-term vascular access for hemodialysis and apheresis. The product is currently awaiting CE Mark approval for this indication in Europe.

About AngioDynamics

AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company’s diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “potential,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company’s expectations. Factors that may affect the actual results achieved by the Company include, without limitation, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of the Company to execute its leadership development plan and integrate purchased businesses, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2009. The Company does not assume any obligation to publicly update or revise any forwardlooking statements for any reason.